Last week, Microsoft announced the release of .NET 10 RC 1, the first of two release candidates ahead of the final version.

Microsoft is expanding .NET developers’ toolset with enhancements to Code Optimizations. This feature is part of Azure ...

Microsoft is signaling a shift in its AI priorities, favoring Anthropic's Claude Sonnet 4 over OpenAI's GPT-5 models in its flagship developer tool, Visual Studio Code.

Although Visual Studio Code is a very useful lightweight code editor, it is actually vanilla Visual Studio that is Microsoft's flagship integrated development environment (IDE). As such, Microsoft ...

Japanese is one of the most studied languages for Australian high school students — but few learn it like Jacinta McIntyre. The 14-year-old from Jamison High School in Penrith is blind and learning ...

Apple has formed a new team to build a ChatGPT-like app, according to Bloomberg’s Mark Gurman. This team — reportedly called Answers, Knowledge, and Information — is working to build an “answer engine ...

StackSocial has brought back one of its most popular Microsoft deals for a limited time. If you enter promo code MSO5 at checkout, you can get a Windows 11 Pro license for only $10. This promotion was ...

Our content is funded in part by commercial partnerships, at no extra cost to you and without impact to our editorial impartiality. Click to Learn More The best AI website builder is Wix, offering an ...

TL;DR? Hear the news as an AI-generated audio overview made using Microsoft 365 Copilot. You can read the transcript here. We’ve entered the era of AI agents. Thanks to groundbreaking advancements in ...

Use Visual Studio to create an Azure resource group project and deploy the resources to Azure. The Azure Resource Group project is now in extended support, meaning we will continue to support existing ...

Microsoft warns that attackers are deploying malware in ViewState code injection attacks using static ASP. NET machine keys found online. As Microsoft Threat Intelligence experts recently discovered, ...

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: A Randomized Controlled Trial ...